Physical examination
Hematologic
Biochemical
Visceral & Pulmonary
Skeletal
Patient-reported Quality-of-Life

Visceral & Pulmonary

Liver and spleen volumes should be measured using volumetric magnetic resonance imaging (MRI) or computed tomography (CT). Ultrasound is not recommended. Although severe pulmonary hypertension occurs in approximately 1% of patients, mild pulmonary hypertension may be found in asymptomatic patients. Thus, pulmonary status should be assessed in all adults by electrocardiogram (ECG), chest X-ray, and Doppler echocardiogram (ECHO) measurement of right ventricular systolic pressure.

Important Safety Information

Adverse reactions related to Cerezyme® (imiglucerase for injection) administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported adverse events include nausea, vomiting, abdominal pain, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Adverse events associated with the route of administration include discomfort, pruritus, burning, swelling or sterile abscess at the site of venipuncture. Symptoms suggestive of hypersensitivity include anaphylactoid reaction, pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis and hypotension. Approximately 15% of patients have developed IgG antibodies; periodic monitoring is suggested. Side effects should be reported promptly to Genzyme Medical Information at 800-745-4447, option 2. To learn more, please see full product information (PDF), or contact Genzyme at 1-800-745-4447.

Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160:2835-2843.

Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004;41(4 suppl 5):15-22.

Mistry, Pramod K., Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Molecular Genetics and Metabolism. 77 (2002) 91-98.